ObvioGo Digital and Hybrid Clinical Trial Platform

ObvioHealth was launched in 2017 by CEO Ivan Jarry as one of the first virtual research organisations and is based in New York. It helps sponsors and CROs run decentralised, hybrid and site-based trials, cutting site visits and improving participant retention and data quality. It reports 62 studies in 40 countries and more than 50,000 consented participants.

Its ObvioGo platform is no-code. Study Designer is a drag-and-drop builder for protocols, workflows and branching logic. Study Manager gives dashboards and alerts for enrolment, safety events and protocol deviations. The participant mobile app handles eConsent, ePRO and eCOA, reminders, coordinator chat, virtual visits and data from wearables and digital therapeutics. Clients include pharmaceutical, consumer health and nutrition companies and CROs such as Novotech.

• Study Designer: drag-and-drop protocol builder with 15+ activity types and reusable templates.
• Study Manager: dashboards for enrolment, tasks, safety events and protocol deviations.
• Participant app: reminders, symptom reporting, coordinator chat and virtual visits.
• eConsent and ePRO/eCOA: validated outcome capture configured inside the platform.
• Device data: automatic ingestion from wearables, sensors and digital therapeutics.
• Integrations: two-way APIs with EHR, EDC, CTMS and RTSM, including Oracle Clinical One.

CROs operating in Vietnam can license ObvioGo to run hybrid studies across several Asian countries. Nutrition and consumer health companies can run app-based studies to support product claims. Hospitals taking part in multinational trials can follow up participants remotely between visits.

Reusable, standardised digital workflows speed study start-up and keep execution consistent across regions, according to the Novotech agreement. Remote assessments and app-based data capture cut the number of site visits for participants. No-code design lets study teams change protocols mid-study with version control and audit trails. One system replaces separate eConsent, ePRO and televisit vendors.

Sponsors increasingly design hybrid trials that mix site visits with remote data capture to recruit faster and reduce dropouts. Asia-Pacific CROs are scaling digital delivery as more biotech trials move to the region. Vietnam's push to grow clinical research capacity creates demand for tools that let local sites take part in decentralised multinational studies.

Founded in 2017 by Ivan Jarry; legal entity Obvio Health USA, Inc., New York. Board includes a former IQVIA Asia-Pacific president who chairs Novotech. Novotech names ObvioHealth its preferred decentralised trial partner. Partnerships with Oracle Life Sciences, SPRIM PRO and Vaxxas. Displays an ISO certified badge.